NCT02191878View on ClinicalTrials.gov

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

July 31, 2016

Conditions
Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell Carcinoma, Adult
Interventions
DRUG

TKM-080301

TKM-080301 intravenous infusion

Trial Locations (15)

10065

Memorial Sloan Kettering Cancer Center, New York

64131

Kansas City Research Institute, Kansas City

75230

Mary Crowley Cancer Research Centers, Dallas

85715

Arizona Clinical Research Center, Tucson

94115

University of California San Francisco, San Francisco

110744

Seoul National University Hospital, Seoul

Unknown

Princess Margaret Hospital, Toronto

Queen Mary Hospital, Hong Kong

National University Hospital, Singapore

Severence Hospital, Yonsei, University Health System, Seoul

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Shuang-Ho Hospital, Taipei

Taipei Veterans General Hospital, Taipei

135-710

Samsung Medical Center, Seoul

138-736

ASAN Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY

NCT02191878 - Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter